Aliases & Classifications for Substance Abuse

MalaCards integrated aliases for Substance Abuse:

Name: Substance Abuse 12 29 15
Substance-Related Disorders 43 71
Substance Abuse Problem 71

Classifications:



External Ids:

Disease Ontology 12 DOID:302
MeSH 43 D019966
NCIt 49 C16522
SNOMED-CT 67 26416006
UMLS 71 C0013146 C0236969 C0740858

Summaries for Substance Abuse

Disease Ontology : 12 A substance-related disorder that involves a maladaptive pattern of substance use leading to significant impairment in functioning.

MalaCards based summary : Substance Abuse, also known as substance-related disorders, is related to depression and cannabis abuse, and has symptoms including symptoms An important gene associated with Substance Abuse is MIAT (Myocardial Infarction Associated Transcript), and among its related pathways/superpathways are Peptide ligand-binding receptors and Transmission across Chemical Synapses. The drugs Ritonavir and Emtricitabine have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and cortex, and related phenotypes are behavior/neurological and cardiovascular system

Wikipedia : 74 Substance abuse, also known as drug abuse, is use of a drug in amounts or by methods which are harmful... more...

Related Diseases for Substance Abuse

Diseases in the Substance Abuse family:

T-Substance Anomaly

Diseases related to Substance Abuse via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 365)
# Related Disease Score Top Affiliating Genes
1 depression 33.6 SLC6A4 MAOA BDNF
2 cannabis abuse 33.4 DRD4 DRD2 COMT BDNF
3 opioid abuse 33.3 DRD5 DRD4 DRD3 DRD2 CYP2D6
4 alcohol use disorder 33.3 SLC6A4 SLC6A3 HTR1B GABRA2 DRD3 DRD2
5 amphetamine abuse 33.3 SLC6A4 SLC6A3 HTR1B DRD5 DRD4
6 eating disorder 33.3 SLC6A4 SLC6A3 NPY DRD3 DRD2 COMT
7 schizoaffective disorder 33.3 SLC6A4 PRL DRD4 DRD3 DRD2 COMT
8 borderline personality disorder 33.2 SLC6A4 SLC6A3 PRL MAOA HTR1B DRD2
9 cocaine abuse 33.1 SLC6A4 SLC6A3 PRL MOBP DRD3 DRD2
10 bipolar disorder 32.9 SLC6A4 SLC6A3 PRL MAOA HTR1B GABRA2
11 schizophrenia 32.5 SLC6A4 SLC6A3 PRL NPY MOBP MIAT
12 personality disorder 32.0 SLC6A4 SLC6A3 PRL MAOA HTR1B DRD4
13 avoidant personality disorder 32.0 SLC6A4 SLC6A3 MAOA HTR1B DRD4
14 drug dependence 31.9 SLC6A4 SLC6A3 NPY GABRA2 DRD3 DRD2
15 brain injury 31.8 DRD2 COMT BDNF
16 alcohol dependence 31.8 SLC6A4 SLC6A3 PRL NPY MAOA HTR1B
17 traumatic brain injury 31.8 DRD2 COMT BDNF
18 opiate dependence 31.8 SLC6A4 SLC6A3 DRD4 DRD3 DRD2
19 disease of mental health 31.8 SLC6A4 SLC6A3 NPY MAOA DRD5 DRD4
20 conduct disorder 31.8 SLC6A4 SLC6A3 MAOA GABRA2 DRD5 DRD4
21 substance dependence 31.7 SLC6A4 SLC6A3 MAOA HTR1B GABRA2 DRD5
22 antisocial personality disorder 31.7 SLC6A4 SLC6A3 PRL MAOA HTR1B GABRA2
23 polysubstance abuse 31.6 DRD3 DRD2 COMT
24 post-traumatic stress disorder 31.6 SLC6A4 NPY MAOA DRD2 DBH COMT
25 cannabis dependence 31.6 GABRA2 DRD2 COMT
26 mood disorder 31.6 SLC6A4 SLC6A3 NPY MAOA HTR1B DRD4
27 mental depression 31.5 SLC6A4 SLC6A3 MAOA HTR1B DRD4 DRD3
28 tobacco addiction 31.5 SLC6A4 SLC6A3 MAOA GABRA2 DRD5 DRD4
29 anxiety 31.4 SLC6A4 SLC6A3 PRL NPY MAOA HTR1B
30 cocaine dependence 31.4 SLC6A4 SLC6A3 PRL HTR1B GABRA2 DRD3
31 alexithymia 31.4 SLC6A4 DRD2 COMT
32 pathological gambling 31.3 SLC6A4 SLC6A3 MAOA DRD5 DRD4 DRD3
33 adjustment disorder 31.3 SLC6A4 NPY BDNF
34 attention deficit-hyperactivity disorder 31.3 SLC6A4 SLC6A3 PRL NPY MAOA HTR1B
35 psychotic disorder 31.3 SLC6A4 SLC6A3 PRL MAOA DRD5 DRD4
36 social phobia 31.3 SLC6A4 PRL MAOA DRD2 COMT BDNF
37 agoraphobia 31.3 SLC6A4 MAOA COMT BDNF
38 anorexia nervosa 31.3 SLC6A4 PRL NPY MAOA DRD4 COMT
39 dysthymic disorder 31.3 SLC6A4 MAOA BDNF
40 sleep disorder 31.2 SLC6A4 SLC6A3 PRL DRD2 BDNF
41 generalized anxiety disorder 31.2 SLC6A4 SLC6A3 NPY MAOA DRD2 CYP2D6
42 bipolar i disorder 31.1 SLC6A4 DRD4 DRD3 DRD2 COMT BDNF
43 postpartum depression 31.1 SLC6A4 PRL MAOA COMT BDNF
44 oppositional defiant disorder 31.1 SLC6A4 SLC6A3 MAOA DRD4 DRD2 DBH
45 major depressive disorder 31.1 SLC6A4 SLC6A3 PRL NPY MAOA HTR1B
46 bulimia nervosa 31.1 SLC6A4 PRL NPY MAOA HTR1B DRD4
47 amnestic disorder 31.0 DRD2 BDNF BCHE
48 tardive dyskinesia 31.0 DRD3 DRD2 CYP2D6 COMT
49 sexual disorder 31.0 SLC6A4 PRL DRD4 DRD3 DRD2 CYP2D6
50 neurotic disorder 31.0 SLC6A4 MAOA BDNF

Graphical network of the top 20 diseases related to Substance Abuse:



Diseases related to Substance Abuse

Symptoms & Phenotypes for Substance Abuse

UMLS symptoms related to Substance Abuse:


symptoms

MGI Mouse Phenotypes related to Substance Abuse:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.22 BDNF COMT CYBB DBH DRD2 DRD3
2 cardiovascular system MP:0005385 9.96 COMT CYBB DBH DRD2 DRD3 DRD5
3 adipose tissue MP:0005375 9.91 CYBB DBH DRD2 DRD3 GABRA2 HTR1B
4 endocrine/exocrine gland MP:0005379 9.81 BDNF COMT DBH DRD2 DRD5 HTR1B
5 homeostasis/metabolism MP:0005376 9.8 BCHE BDNF COMT CYBB DBH DRD2
6 nervous system MP:0003631 9.5 BDNF COMT CYBB DBH DRD2 DRD3

Drugs & Therapeutics for Substance Abuse

Drugs for Substance Abuse (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 480)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
2
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
3
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
4
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
5
Nicotine Approved Phase 4 54-11-5 942 89594
6
Lithium carbonate Approved Phase 4 554-13-2
7
Peginterferon alfa-2b Approved Phase 4 99210-65-8, 215647-85-1
8
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
9
Desipramine Approved, Investigational Phase 4 50-47-5 2995
10
Memantine Approved, Investigational Phase 4 19982-08-2 4054
11
Clonidine Approved Phase 4 4205-90-7 2803
12
Baclofen Approved Phase 4 1134-47-0 2284
13
Amantadine Approved Phase 4 768-94-5 2130
14
Histamine Approved, Investigational Phase 4 51-45-6 774
15
Mirtazapine Approved Phase 4 85650-52-8, 61337-67-5 4205
16
Acetaminophen Approved Phase 4 103-90-2 1983
17
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
18
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
19
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
20
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
21
Ziprasidone Approved Phase 4 146939-27-7 60854
22
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
23
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
24
Chlorpromazine Approved, Investigational, Vet_approved Phase 4 50-53-3 2726
25
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
26
Amphetamine Approved, Illicit, Investigational Phase 4 300-62-9 5826 3007
27
Dextroamphetamine Approved, Illicit Phase 4 51-64-9 5826
28
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
29
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
30
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
31
Dronabinol Approved, Illicit Phase 4 1972-08-3 16078
32
Sofosbuvir Approved Phase 4 1190307-88-0 45375808
33
Velpatasvir Approved, Investigational Phase 4 1377049-84-7 67683363
34
Carbon monoxide Approved, Investigational Phase 4 630-08-0 281
35
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
36
Brexpiprazole Approved, Investigational Phase 4 913611-97-9 11978813
37 sodium fluoride Approved Phase 4 7681-49-4
38
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
39
Rifapentine Approved, Investigational Phase 4 61379-65-5 6323497
40
Isoniazid Approved, Investigational Phase 4 54-85-3 3767
41
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 9552079 2713
42
Levonorgestrel Approved, Investigational Phase 4 797-63-7, 17489-40-6 13109
43
Etonogestrel Approved, Investigational Phase 4 54048-10-1 40976 6917715
44
Oxytocin Approved, Vet_approved Phase 4 50-56-6 53477758 439302
45
Cocaine Approved, Illicit Phase 4 50-36-2 446220 5760
46
Methadone Approved Phase 4 76-99-3 4095
47
Clozapine Approved Phase 4 5786-21-0 2818
48
Morphine Approved, Investigational Phase 4 57-27-2 5288826
49
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
50
Oxymorphone Approved, Investigational, Vet_approved Phase 4 76-41-5 5284604

Interventional clinical trials:

(show top 50) (show all 2107)
# Name Status NCT ID Phase Drugs
1 Cognitive Correlates of Substance Abuse, Part 1 Unknown status NCT00000346 Phase 4
2 An Evaluation of Innovative Methods for Integrating Buprenorphine Opioid Treatment in HIV Primary Care Settings Unknown status NCT00124358 Phase 4 Buprenorphine
3 Study of Associated Gene Polymorphisms With Atomoxetine Response Prediction in ADHD Treatment Unknown status NCT01339286 Phase 4 atomoxetine
4 Association Between Motorcycle Accidents, Attention Deficit/Hyperactivity Disorder and Substance Use Disorder and Motorcycle Accidents Unknown status NCT00536419 Phase 4 Methylphenidate
5 Aggressive Behaviour in Children With Tourette's Syndrome (TS) and Comorbid Attention Deficit Hyperactivity Disorder (ADHD) Unknown status NCT00152750 Phase 4 APO-clonidine
6 Three Strategies for Implementing Motivational Interviewing on Medical Inpatient Units: See One, Do One, Order One Unknown status NCT01825057 Phase 4
7 A Controlled Study of the Efficacy of Botulinum Toxin A (Botox) for the Treatment of Major Depressive Disorder (MDD) Unknown status NCT01556971 Phase 4 Botox;Saline Solution
8 A Multi-Center,Open-Labeled,Intervention Study:The Efficacy And Safety Of Intramuscular Ziprasidone For Three Days In Patients With Psychotic Agitation Unknown status NCT02935998 Phase 4 Ziprasidone
9 An Open-label, Randomised Pilot Study Comparing the Efficacy, Safety and Tolerability of Raltegravir With Protease Inhibitor-based Therapy in Treatment-naïve, HIV/Hepatitis C Co-infected Injecting Drug Users Receiving Methadone Unknown status NCT01105611 Phase 4 Raltegravir;Atazanavir/Ritonavir
10 Depakote ER Therapy for Mania Comorbid With Substance Abuse Completed NCT00208195 Phase 4 Divalproex ER
11 Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM) Completed NCT00798538 Phase 4
12 The Impact of Quetiapine on the Drug Abuse Patterns of Addicted Schizophrenic Patients Completed NCT00295412 Phase 4 quetiapine (drug)
13 Pilot Study of Vyvanse™ (Lisdexamfetamine Dimesylate) in Adolescents (Ages 11-15) With ADHD and an Older Sibling With ADHD and Substance Dependence Completed NCT00573534 Phase 4 Vyvanse
14 Smoking Cessation Treatment for Methadone Maintenance Patients Completed NCT01027754 Phase 4 Varenicline;Placebo
15 Aripiprazole (Abilify) Therapy for Reducing Comorbid Substance Abuse Completed NCT00208169 Phase 4 Aripiprazole
16 Relapse Prevention With Varenicline Completed NCT00944554 Phase 4 Varenicline;Placebo
17 Translating Depression Guidelines Into Substance Abuse Treatment Completed NCT00137306 Phase 4
18 A Double-blind Placebo Controlled Trial of Pregnenolone for Depression in Patients With Bipolar Disorders or Recurrent Major Depressive Disorder and a History of Substance Abuse Completed NCT00223197 Phase 4 Pregnenolone
19 Buprenorphine to Improve HIV Care Engagement and Outcomes: A Randomized Trial (BRAVO) Completed NCT01936857 Phase 4 Buprenorphine/naloxone;Methadone Maintenance Therapy
20 On-Site Addiction Treatment With Buprenorphine in HIV Clinical Care Settings Completed NCT00317460 Phase 4
21 Psychoeducation Reaches HCV-infected Methadone/Buprenorphine Substituted Patients in Standard Antiviral Treatment Completed NCT00844272 Phase 4
22 Seroquel (Quetiapine) Therapy for Schizophrenia and Schizoaffective Disorders and Comorbid Cocaine and/or Amphetamine Abuse/Dependence: A Comparative Study With Risperidone Completed NCT00208143 Phase 4 Quetiapine;Risperidone
23 Divalproex ER vs. Risperidone for Bipolar Disorder With Comorbid Substance Use Disorder Completed NCT00203528 Phase 4 divalproex sodium ER;risperidone
24 Atomoxetine in Adolescents With Attention Deficit Hyperactivity Disorder (ADHD) and Substance Use Disorder (SUD) Completed NCT00218322 Phase 4 Atomoxetine hydrochloride;Placebo
25 Improving Hepatitis C Treatment in Injection Drug Users Completed NCT00148031 Phase 4 Pegylated Interferon and Ribavirin
26 Methamphetamine Abuse Pharmacology in Patients With AIDS Completed NCT00000321 Phase 4 Desipramine
27 Paroxetine Treatment in Outpatients With Comorbid PTSD and Substance Dependence Completed NCT00330239 Phase 4 Paroxetine CR
28 Prevention Services in Schools for Early Drug Abuse Risk Completed NCT00257088 Phase 4
29 Efficacy of Quetiapine in the Reduction of Cocaine Use and Cravings in Individuals With Cocaine Dependence Completed NCT00232336 Phase 4 quetiapine
30 Efficacy of Quetiapine in Treating Patients With Active Substance Use Disorder and Schizophrenia Completed NCT00156715 Phase 4 Quetiapine
31 Efficacy & Safety of Baclofen to Reduce Alcohol Use in Veterans With HCV Completed NCT01008280 Phase 4 baclofen;placebo
32 Bupropion for ADHD in Adolescents With Substance Use Disorder Completed NCT00936299 Phase 4 Bupropion
33 Brain Changes in Stimulant Dependent Subjects Completed NCT00000343 Phase 4
34 Pharmacotherapy and Intensive Treatment Completed NCT00000218 Phase 4 Carbamazepine
35 Methylphenidate Raclopride PET Test Completed NCT00015301 Phase 4 Methylphenidate
36 Pathophysiological Subtyping of Abnormalities in Cocaine Dependence Completed NCT00015275 Phase 4
37 Modeling Impaired Judgement in Cocaine Abusers Completed NCT00015236 Phase 4
38 A Prospective Cohort Study Comparing the Effectiveness of Zepatier for the Treatment of Hepatitis C in an Academic Center Population to People Who Inject Drugs (PWIDs) in a Safety Net Clinic Setting Engaged in Either a Medication Assisted Therapy (MAT) or Syringe Exchange Program Completed NCT03093415 Phase 4 elbasvir-grazoprevir (50 mg/100 mg)
39 Effectiveness of Naltrexone in a Community Setting Completed NCT00000445 Phase 4 naltrexone (Revia)
40 Abuse Liability of Controlled-Release Oxycodone Formulations Completed NCT02101840 Phase 4 Apo-Oxycodone CR®;OxyNEO®;Placebo
41 Intervention of HIV, Drug Use and the Criminal Justice System in Malaysia Completed NCT02396979 Phase 4 Methadone
42 Buprenorphine/Nx Treatment of Heroin Dependence-A Compassionate Use Study Completed NCT00015340 Phase 4 Buprenorphine/naloxone
43 A Randomized Acceptability and Safety Study of the Transfer From Subutex to Suboxone in Opioid- Dependent Subjects Completed NCT00605033 Phase 4 Suboxone, Buprenorphine Hydrochloride + Naloxone, SCH 484;Subutex, Buprenorphine Hydrochloride, SCH 28444
44 The Effects of Intranasal Oxytocin on Social Cognition, Implicit Preferences and Craving in Moderate to Heavy Social Alcohol Drinkers Completed NCT01829516 Phase 4 Oxytocin;Placebo
45 Drug Contextual Conditioning With in Humans: Causes and Consequences Completed NCT03075501 Phase 4 Stimulant or sedative;Placebo
46 Substance Dependent Teens - Impact of Treating Depression Study 1 Completed NCT00061113 Phase 4 Fluoxetine + outpatient cognitive behavioral therapy;fluoxetine;placebo + CBT
47 Reinforcement-Based Treatment and Abstinence-Contingent Housing for Drug Abusers Completed NCT00685620 Phase 4
48 Treatment of Acute Hepatitis C Virus Infection in Injection Drug Users With Pegylated Interferon for 24 Weeks Completed NCT00194480 Phase 4 Pegylated Interferon
49 Vilazodone for Separation Anxiety Disorder Completed NCT01999920 Phase 4 Vilazodone;Placebo
50 A Multicentre, Randomised, Open-label, Active-controlled Trial of the Effectiveness of Buprenorphine/Naloxone in Reducing Intravenous Buprenorphine Misuse in France Completed NCT00955162 Phase 4 Buprenorphine (Subutex);Buprenorphine/naloxone (Suboxone)

Search NIH Clinical Center for Substance Abuse

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Desipramine
Desipramine Hydrochloride
Doxapram
Doxapram Hydrochloride

Cochrane evidence based reviews: substance-related disorders

Genetic Tests for Substance Abuse

Genetic tests related to Substance Abuse:

# Genetic test Affiliating Genes
1 Substance Abuse 29

Anatomical Context for Substance Abuse

MalaCards organs/tissues related to Substance Abuse:

40
Brain, Testes, Cortex, Liver, Heart, Spinal Cord, Prefrontal Cortex

Publications for Substance Abuse

Articles related to Substance Abuse:

(show top 50) (show all 24014)
# Title Authors PMID Year
1
"If you don't behave, you're in real shit, you don't get outside the doors"-a phenomenological hermeneutic study of adolescents' lived experiences of the socio-spatial environment of involuntary institutional care. 61
32049605 2020
2
Historical trends of admitted patients by selected substances and their significant patient's level factors. 61
32497957 2020
3
Jamaican adolescents' receptiveness to digital mental health services: A cross-sectional survey from rural and urban communities. 61
32455121 2020
4
Orbitofrontal, dorsal striatum, and habenula functional connectivity in psychiatric patients with substance use problems. 61
32371303 2020
5
Screen printed electrode-based biosensor functionalized with magnetic cobalt/single-chain antibody fragments for cocaine biosensing in different matrices. 61
32498832 2020
6
Unintended pregnancy prevention in women using psychoactive substances: A systematic review. 61
32200197 2020
7
Goal commitment evolution in a Spanish adolescent sample with cannabis use disorder. 61
32208323 2020
8
Women's Barriers to Specialty Substance Abuse Treatment: A Qualitative Exploration of Racial/Ethnic Differences. 61
31531756 2020
9
Trends in documented cannabis use disorder among hospitalized adult epilepsy patients in the United States. 61
32361206 2020
10
Test-retest reliability of fMRI-measured brain activity during decision making under risk. 61
32205253 2020
11
Barriers in seeking support: Perspectives of service providers who are survivors of sexual violence. 61
32207152 2020
12
Syndemics of HIV with mental illness and other noncommunicable diseases: a research agenda to address the gap between syndemic theory and current research practice. 61
32487814 2020
13
The practitioners' perspective on the upside and downside of applying social capital concept in therapeutic settings. 61
32045091 2020
14
Legal aspects of information sharing and communication by poison centers in the United States. 61
31935123 2020
15
What constitutes a syndemic? Methods, contexts, and framing from 2019. 61
32412998 2020
16
Assessment of motivational interviewing with the VASE-(Mental) Healthcare: Mixed-methods study to examine feasibility and validity in the general practice setting. 61
32115312 2020
17
"Operator syndrome": A unique constellation of medical and behavioral health-care needs of military special operation forces. 61
32052666 2020
18
Antipsychotic-induced Hyperprolactinemia in aging populations: Prevalence, implications, prevention and management. 61
32243999 2020
19
Cannabis use during adolescence and the occurrence of depression, suicidality and anxiety disorder across adulthood: Findings from a longitudinal cohort study over 30 years. 61
32379627 2020
20
Comorbid Conditions in Relation to Controlled Substance Abuse. 61
32448457 2020
21
Hyperexcitability of VTA dopaminergic neurons in male offspring exposed to physical or psychological prenatal stress. 61
32173457 2020
22
Physician and behavioral health provider diagnostic agreement in a general hospital setting. 61
32046539 2020
23
Is the "Mission Accomplished" for the Management of Acute Oral Pain without Enabling Substance Abuse? 61
32567991 2020
24
Machine-learning approaches to substance-abuse research: emerging trends and their implications. 61
32304429 2020
25
The Effects of Mental Health and Substance Abuse/Dependence Disorders on Prison Misconduct Among Male Inmates in Taiwan. 61
31884841 2020
26
Differential implications of persistent, remitted, and late-onset ADHD symptoms for substance abuse in women and men: A twin study from ages 11 to 24. 61
32444170 2020
27
Intimate Partner Violence Among Female OEF/OIF/OND Veterans Who Were Evaluated for Traumatic Brain Injury in the Veterans Health Administration: A Preliminary Investigation. 61
29294714 2020
28
Opioid Consumption After Gender-Affirming Mastectomy and Two Other Breast Surgeries. 61
32109744 2020
29
R-(-)-ketamine modifies behavioral effects of morphine predicting efficacy as a novel therapy for opioid use disorder1. 61
32333922 2020
30
Nurse-Led Initiative to Improve Addiction Services: An Interdisciplinary Approach. 61
32511177 2020
31
Substance use in youth at-risk for serious mental illness. 61
32500614 2020
32
Influenza Associated Aspergillosis: Nationwide Trends, Predictors and Outcomes from 2005-2014. 61
32565269 2020
33
Nephrotic syndrome and pulmonary hypertension as complications of intravenous drug abuse. 61
32564430 2020
34
Tuberculin skin test and predictive host factors for false-negative results in patients with pulmonary and extrapulmonary tuberculosis. 61
32052551 2020
35
The "Parma-Early Psychosis" program: General description and process analysis after 5 years of clinical activity. 61
31758672 2020
36
Depression and its association with adverse childhood experiences in people with substance use disorders and comorbid medical illness recruited during medical hospitalization. 61
32563021 2020
37
How to prevent the malignant progression of bipolar disorder. 61
32578689 2020
38
International research into 22 years of use of chemical restraint: An evidence overview. 61
31318109 2020
39
Missed opportunities for NCD multimorbidity prevention in adolescents and youth living with HIV in urban South Africa. 61
32487118 2020
40
Determinants of substance use among young people attending an urban primary health center in Delhi. 61
32474456 2020
41
Summarizing Complex Graphical Models of Multiple Chronic Conditions Using the Second Eigenvalue of Graph Laplacian: Algorithm Development and Validation. 61
32554376 2020
42
[Smoke-free Germany 2040: a discussion paper]. 61
32572868 2020
43
[Pilot study on subjectively and objectively measurable stress reduction in the daily routine of a university anesthesia department by an intervention program according to mindfulness-based stress reduction]. 61
32561949 2020
44
A Web-Based Intervention for Young Adults Whose Parents Have a Mental Illness or Substance Use Concern: Protocol for a Randomized Controlled Trial. 61
32554368 2020
45
HIV Neuropathogenesis in the Presence of a Disrupted Dopamine System. 61
32506353 2020
46
Hormonal responses in gambling versus alcohol abuse: A review of human studies. 61
32004637 2020
47
Investigating Mental Health Implications for Drug Court Participants. 61
32538260 2020
48
Children's Mental Health Emergency Department Visits: 2007-2016. 61
32393605 2020
49
Laryngeal Pathologies and Their Associations With Mental Health Disorders. 61
32511753 2020
50
Mental Health Stigma and Wellbeing Among Commercial Construction Workers: A Mixed Methods Study. 61
32541624 2020

Variations for Substance Abuse

Expression for Substance Abuse

Search GEO for disease gene expression data for Substance Abuse.

Pathways for Substance Abuse

Pathways related to Substance Abuse according to GeneCards Suite gene sharing:

(show all 24)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.48 PRL NPY HTR1B GABRA2 DRD5 DRD4
2
Show member pathways
12.87 SLC6A4 SLC6A3 MAOA GABRA2 COMT BCHE
3
Show member pathways
12.69 DRD5 DRD4 DRD3 DRD2 BDNF
4
Show member pathways
12.58 SLC6A3 MAOA DRD5 DRD4 DRD3 DRD2
5 12.23 DRD5 DRD4 DRD3 DRD2
7 12.17 NPY HTR1B DRD5 DRD2 BDNF
8
Show member pathways
11.88 SLC6A3 MAOA DRD2 BDNF
9
Show member pathways
11.79 DRD4 DRD3 DRD2
10
Show member pathways
11.79 SLC6A4 CYP2D6 CYP2C19 COMT
11 11.72 SLC6A4 MAOA HTR1B CYP2D6 CYP2C19
12
Show member pathways
11.64 MAOA DBH COMT
13
Show member pathways
11.6 HTR1B DRD5 DRD4 DRD3 DRD2
14
Show member pathways
11.53 CYP2D6 CYP2C19 COMT
15 11.27 MAOA CYP2D6 CYP2C19
16
Show member pathways
11.26 SLC6A4 SLC6A3 MAOA DBH
17 11.12 SLC6A4 MAOA HTR1B
18
Show member pathways
10.98 MAOA DBH COMT
19 10.88 PRL NPY DRD2
20
Show member pathways
10.82 MAOA